United States: Novo Nordisk is partnering with Septerna to create new drugs in pill form to address obesity, type 2 diabetes, and other metabolic disorders.
A $3 Billion+ Deal in the Making
Septerna could earn up to $2.2 billion as a result of the collaboration. It also provides up to $800 million more in long-term financial incentives. Septerna will receive a portion of every dollar generated from the sale of any future products, the Wall Street Journal has learned, as reported by HealthDay.
Every dollar spent on early-stage work for the project will come from the Danish drugmaker.
Targeting GPCRs — The Key to Oral Meds
Septerna has created a platform that helps discover and develop drugs for G protein-coupled receptors.
GPCRs assist in moving molecules across the cell membrane. A large number of medications currently available for use are developed to interact with GPCRs.
